Bimal Bhindi

@BBhindi

Husband | Father | Urologic Oncologist at Southern Alberta Institute of Urology, Univ. of Calgary | Clinical Epidemiologist | Views are my own

Joined February 2014

Tweets

You blocked @BBhindi

Are you sure you want to view these Tweets? Viewing Tweets won't unblock @BBhindi

  1. Retweeted
    28 Dec 2018
    Replying to

    Consistent with paper by a few years ago. Type 1 and Type 2 have similar prognosis after adjusting for other factors (size, stage, grade etc)

    Undo
  2. 15 Dec 2018

    My 2yo daughter is growing up too fast. Just fulfilled a 16yo milestone and demanded pizza for breakfast.

    Undo
  3. Retweeted
    12 Dec 2018

    When this trial began accruing, I was a first year Medical student. Solid clinical data is often at the mercy of a disease’s natural history. So few have had the fortitude to provide as definitive data as this in a cancer with decades as units. Thank you.

    Undo
  4. Retweeted
    11 Dec 2018

    Systematic review of role of cytoreductive nephrectomy in the targeted therapy era and beyond

    Undo
  5. Retweeted
    8 Dec 2018

    This systematic review and analysis finds that for oncology patients, improvement in does not correlate with improvement in

    Undo
  6. Retweeted
    5 Dec 2018

    Very interesting study. Only 4 bladder cancer patients included but radical cystectomy patients after neoadjuvant chemo certainly one of highest risk groups for VTE. How many Pre-op cystectomy patients have an asymptotic DVT post chemo?

    Undo
  7. Retweeted
    19 Nov 2018

    Hellooooo, urotwitterati! We’re inaugurating the journal club next Wednesday Nov 28 20:00EST. Spread the word 🤘🤘🤘 Hoping our old crew & our pals will crack their knuckles & join the discussion. Details and download link to come

    Undo
  8. Retweeted
    12 Nov 2018
    Show this thread
    Undo
  9. Retweeted
    9 Nov 2018

    Amazing talk by on role of nephrectomy! Consider risk adapted approach!

    Undo
  10. Retweeted
    7 Nov 2018

    Surgical commandments. Words to live by at all stages of training. From Dr Brandes

    Undo
  11. Retweeted
    3 Nov 2018

    Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium

    Undo
  12. Retweeted
    1 Nov 2018

    Outstanding effort from and Eddy Fan -- discussing challenges of procedural RCTs, offering solutions, and highlighting the importance of well designed observational studies

    Undo
  13. 3 Nov 2018

    A true honor to collaborate w/ this insightful & thoughtful group of clinicians: K. Bensalah J. Karam T. Powles() & Axel Bex. CN still has a role, but CARMENA should push us to be more selective in how we use it

    Undo
  14. Retweeted
    21 Oct 2018

    Abiraterone plus prednisolone improves OS in BOTH high risk/ high volume and low volume/low risk patients with hormone naive metastatic prostate cancer

    , , and 7 others
    Undo
  15. Retweeted
    21 Oct 2018

    STAMPEDE M1RT comparison results now online in the . SOC+ prostate RT improves OS and FFS in oligometastatic patients. Results presented at

    Undo
  16. Retweeted
    18 Oct 2018

    Exciting press release about improved OS with pembro and axitinib in . Upon approval will have many choices first line and will need RWE to help compare. Are there differences in PD(L)1 inhibitors and is access to CTLA4 crucial?

    Undo
  17. 6 Oct 2018

    My daughter can now swipe cell phone apps to find and activate her white noise. I'm going to be obsolete sooner than I thought.

    Undo
  18. Retweeted
    6 Oct 2018

    It was an honor to present this to the pioneers of the field Arthur Smith @EndourolSoc

    Undo
  19. Retweeted
    3 Oct 2018

    Reminder by to consider conditional life expectancy when discussing options with older patients

    Undo
  20. 1 Oct 2018

    Nice number of votes, interesting results, appreciate all the input,. Would love to hear from those who felt having a solitary kidney wouldn't impact approach re: thoughts on ischemia time and cooling the bean.

    Show this thread
    Undo

Loading seems to be taking a while.

Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.

    You may also like

    ·